New Approach Entails a Defined Antibody
Combination Targeting Multiple Epitopes and Mechanisms of Viral
Evasion
VICTORIA, March 12, 2020 /CNW/ - IMMUNOPRECISE ANTIBODIES
LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (OTC QB: IPATF),
following its announcement to develop innovative treatments
against the new coronavirus, SARS-CoV-2, unveils its unique
approach utilizing PolyTope mAb TherapyTM, enabled
by IPA's diverse discovery platforms and artificial intelligence
capabilities with their partner, EVQLV, Inc., in the development of
a universal COVID-19 therapy.
![ImmunoPrecise Antibodies Ltd. (CNW Group/ImmunoPrecise Antibodies Ltd.) ImmunoPrecise Antibodies Ltd. (CNW Group/ImmunoPrecise Antibodies Ltd.)](https://mma.prnewswire.com/media/1123245/ImmunoLogo_1.jpg)
Current vaccine strategies under development for SARS-CoV-2 are
being designed to protect uninfected individuals, however, this
does not address the patients with active disease. Antibody
therapies represent a potentially powerful treatment option for
COVID-19 patients, however, the current, proposed curative options
(including polyclonal, sensitized serum or individual monoclonal
antibody therapies) are potentially susceptible to escape by viral
mutation and are likely not broadly effective against multiple
strains, leaving segments of the population untreatable.
"Given the continuous increase in information on SARS-CoV-2
transmission, and seemingly higher than predicted mutation rates,
we believe that traditional treatments and diagnostics targeting
limited epitopes may present a significant liability for long-term
efficacy of a therapeutic, vaccine or diagnostic", stated
ImmunoPrecise CEO and president, Dr. Jennifer Bath.
The emerging SARS-CoV-2 virus, and other new (related)
pathogens, requires the rapid development of broadly effective
treatments and vaccines. Given its biology, developing an
effective therapeutic workplan for treating SARS-CoV-2 infection
required a sophisticated approach that considered multiple
mechanisms of immune system involvement, the predictability of
mutations within the virus genome, and other attributes with the
potential to provide maximum clinical benefit for both current and
future variants of the virus.
Ilse Roodink, Chairwoman of Talem's Scientific Advisory
Committee and Coronavirus Global Project Leader emphasized,
"Our PolyTope mAb Therapy™ perfectly combines the benefits of
using well-defined and fully characterized monoclonal antibodies
with the essential need for a multi-targeting strategy to tackle
this quickly emerging virus, thereby significantly accelerating
effective clinical application".
About ImmunoPrecise Antibodies Ltd.
ImmunoPrecise is a full-service, therapeutic antibody discovery
Contract Research Organization offering species agnostic,
multi-format, characterized and engineered, human monoclonal
antibodies, on an abbreviated timeframe, for its pharmaceutical
clients. For further information, visit
www.immunoprecise.com or contact solutions@immunoprecise.com.
There is no assurance that ImmunoPrecise will be successful in the
development of a vaccine and/or therapeutic against the new
coronavirus.
Forward Looking Information
This news release contains statements that, to the extent
they are not recitations of historical fact, may constitute
"forward-looking statements" within the meaning of applicable
Canadian securities laws. The Company uses words such as "may",
"would", "could", "will", "likely", "expect", "believe", "intend"
and similar expressions to identify forward-looking statements. Any
such forward-looking statements are based on assumptions and
analyses made by ImmunoPrecise in light of its experience and its
perception of historical trends, current conditions and expected
future developments. However, whether actual results and
developments will conform to ImmunoPrecise's expectations and
predictions is subject to any number of risks, assumptions and
uncertainties. Many factors could cause ImmunoPrecise's actual
results to differ materially from those expressed or implied by the
forward-looking statements contained in this news release. Such
factors include, among other things, actual revenues and earnings
for IPA being lower than anticipated, and those risks and
uncertainties described in ImmunoPrecise's annual management
discussion and analysis for the fiscal year ended January 31, 2020 which can be accessed at
www.sedar.com. The "forward-looking statements" contained
herein speak only as of the date of this press release and, unless
required by applicable law, ImmunoPrecise undertakes no obligation
to publicly update or revise such information, whether as a result
of new information, future events or otherwise.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/immunoprecise-announces-the-launch-of-polytope-mab-therapy-to-tackle-coronavirus-pandemic-301022138.html
SOURCE ImmunoPrecise Antibodies Ltd.